drugset
drugset / Trial / NCT04686383

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

NCT04686383 ↗

Phase 1 Completed 17 enrolled Calgent Biotechnology Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multi-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of CAL056 mesylate in cancer patients with resistant or refractory solid tumors.

Timeline

Start
2020-12-29
Primary completion
2022-06-07
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CAL056 Unknown 20 mg Oral
Subject CAL056 Unknown 40 mg Oral
Subject CAL056 Unknown 80 mg Oral
Subject CAL056 Unknown 120 mg Oral
Subject CAL056 Unknown 160 mg Oral

Indications

refractory malignant neoplasm